Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06655389

Correlation Between PLA Levels and Disease Severity in Patients With Sepsis Cardiac Insufficiency

Status
Recruiting
Phase
Study type
Observational
Enrollment
30 (estimated)
Sponsor
Dongzhimen Hospital, Beijing · Academic / Other
Sex
All
Age
50 Years – 90 Years
Healthy volunteers
Accepted

Summary

Sepsis cardiac insufficiency is characterized by high morbidity and mortality. Studies have shown an association between elevated PLA levels in patients with sepsis and clinical outcomes of cardiac dysfunction. This study will explore the correlation between circulating PLA levels and organ dysfunction and disease severity in SIMD patients in the form of a cross-sectional study.

Detailed description

Sepsis cardiac insufficiency is an unsolved problem in the field of severe disease, which is characterized by high morbidity and high mortality. Several studies have found that infectious factors activate platelets and inflammatory cells, damage the vascular endothelium, and cause leukocytes to interact with platelets to form platelet-leukocyte aggregates, and elevated PLA levels in patients with sepsis are associated with the clinical outcome of cardiac dysfunction. The literature studies have shown that the serum PLA level in sepsis patients is significantly increased, and the PLA level is positively correlated with the severity of cardiac dysfunction in sepsis patients, and the formation of PLA is regulated by the binding of CD62P on the surface of activated platelets and PSGL-1 on the surface of leukocytes. This study will explore the correlation between circulating PLA levels and organ dysfunction and disease severity in patients with SIMD in the form of a cross-sectional study, in order to provide a new potential direction for the evaluation and treatment of SIMD.

Conditions

Timeline

Start date
2024-05-01
Primary completion
2026-12-31
Completion
2026-12-31
First posted
2024-10-23
Last updated
2024-10-23

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06655389. Inclusion in this directory is not an endorsement.